4 Spotlight Stocks Making Rounds

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Activision Blizzard (NASDAQ:ATVI) launches one of the most awaited video games of the shopping season on Tuesday – Call of Duty: Black Ops II – which marks the most recent offering in Activision’s top-selling Call of Duty military combat series. Even though some observers believe that the product might be the number-one selling game of 2012, investors thus far have been avoiding Activision shares, which have basically flat-lined for three years. Meanwhile, GameStop Corp. (NYSE:GME) and Best Buy Co. (NYSE:BBY) stores are conducting midnight sales events for the game. Activision shares did wind up in the green on Monday, but just barely.

Hewlett-Packard Co.  (NYSE:HPQ) sees Barclays Capital maintain its Equal weight on its shares on Monday with a price target of $14.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now.

Nvidia Corporation (NASDAQ:NVDA) shares fell by around 3.86 percent Friday to $12.19, with more than 21.15 million shares traded in the session, as opposed to its average volume of 10.26 million shares. For the past 12 months, shares have been traded inside a range of $11.63 to $16.90.

Vivus (NASDAQ:VVUS) announces that a study indicated that Phentermine and Topiramate extended-release capsules improved cardiovascular risk factors, obstructive sleep apnea, and weight loss after 28 weeks. The firm currently markets Phentermine and Topiramate extended-release capsules as Qsymia, which is approved domestically for chronic weight management in adults, but the medication is not approved for the treatment of obstructive sleep apnea. Vivus reported that the current standard of treatment for OSA is positive airway pressure, in which increased air pressure maintains an open airway. Additionally, the firm believes that a pharmacologic treatment might be useful and more acceptable to some patients than the pressure, but right now, no drug has been approved to treat the condition.

Don’t Miss: Can Star Scientific Leave its Big Tobacco Past Behind?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business